Abstract. One hundred and fifty patients with severe falciparum malaria were administered sequential combination of dihydroartemisinin suppository followed by an oral mefloquine tablet. Dihydroartemisinin suppositories (80 mg/ capsule) were given rectally once daily for 3 days with a total dose of 8-10 mg/kg. Two doses of mefloquine, 15 mg/kg/dose and 10 mg/kg/dose, were given at 72 hr and 84 hr, respectively. The mean [SD] parasite clearance time and fever clearance time were 46.1 [15.7] hr and 82.5 [59.6] hr, respectively. No death or major adverse drug effects occurred. The cure rate at 28 days of inpatient follow-up was 95% (113 of 119 patients). In severe malaria, dihydroartemisinin suppository followed by oral mefloquine is a suitable alternative treatment to parenteral drugs.
INTRODUCTION
Severe falciparum malaria carries a mortality rate ranging from 10% to 40% 1 depending upon available facilities, standard of care, and clinical presentation on admission to the hospital. The high mortality rate of severe malaria could be reduced if early treatment were initiated to reduce parasitemia as quickly as possible and thus prevent further complications. Severe malaria often requires parenteral treatment until oral medications are tolerated. However, the majority of severe malaria cases occur in rural areas where parenteral antimalarials may not be available. Devices for injectable treatment are expensive and require relatively sophisticated facilities. In contrast, rectal formulations of artemisinin derivatives are easy to administer, even by unskilled personnel, in remote areas where facilities are limited. The supply of suppository forms of artemisinin derivatives is currently limited mainly to China and Vietnam. [2] [3] [4] [5] [6] WHO/TDR is developing artesunate in a rectal formulation as a pre-referral treatment of falciparum malaria to prevent severe disease. Such treatment must be followed by a definitive course of either oral or injectable therapy. 7 Recently, dihydroartemisinin (DHA) was formulated in oral form in Thailand under the auspices of the Thailand-Tropical Disease Research Programme (T-2 Programme, a research program funded jointly by the Thai government and WHO/TDR). The present noncomparative clinical trial was set up to evaluate the safety and efficacy of dihydroartemisinin suppository followed by mefloquine in the treatment of severe malaria in adult Thai patients. Rectal treatment with DHA was followed by a full course of mefloquine at 25 mg/kg in two divided doses. The efficacy and safety of such sequential treatment regimens has been confirmed in prior trials. [8] [9] All artemisinin derivatives after entering to human body will be converted to dihydroartemisinin (an active metobolite). The use of dihydroartemisinin would be two-fold benefit as its easy to formulate and its low cost. This study is designed as the previous two trials. [8] [9] However, the difference is only the use of its metabolite that might be an alternative treatment for severe malaria.
PATIENTS AND METHODS
Patients with severe and moderately-severe falciparum malaria admitted to the Bangkok Hospital for Tropical Diseases between March and September 1999, were studied. Patients were considered to have severe falciparum malaria if they were unarousable, had renal impairment (serum creatinine concentration Ͼ 265 mol/L (3 mg/dl) after rehydration), jaundice (serum bilirubin concentration Ͼ 50 mol/L (3 mg/dl)), hyperparasitemia (greater than 100,000 parasites/ L), the presence of schizonts, or severe anemia (hemoglobin Ͻ5 g/dl). Patients were considered to have moderately severe disease if they had severe vomiting and were unable to take oral medications or had raised serum transaminase(s) (defined as Ͼ 50 U/L), but did not have the above manifestations of severe malaria. Patients were enrolled if they were 5 years of age or older, if informed consent to take part in the study was provided by the patient or relatives, and if the patient agreed to remain in the hospital for 28 days. Reasons for exclusion were pregnancy, acute diarrhea, abnormalities of the anus or rectum such as hemorrhoids, rectal prolapse, anal abscesses or fissures, or previous anus and rectal surgery, or pretreatment with antimalarial drugs within the past two weeks. This study was approved by the Ethical Committee of the Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Upon admission to the ward, patients meeting inclusion criteria received DHA suppositories (80 mg/capsule) given rectally according to body weight. DHA was given once daily for 3 days with total dose of 8-10 mg/kg. Dosage was as follows: 1) patients with body weight of less than 30 kg were given 1 capsule once daily for 3 days, 2) patients with body weight of 30-40 kg were given 2 capsules once daily on the first day followed by 1 capsule once daily for 2 days; 3) patients with body weight of 41-50 kg were given 2 capsules once daily for 2 days followed by 1 capsule once daily for 1 day; 4) patients with body weight of 51-60 kg were given 2 capsules once daily for 3 days; 5) patients with body weight of 61-70 kg were given 3 capsules once daily for 1 day followed by 2 capsules once daily for 2 days; 6) patients with body weight of 71-80 kg were given 3 capsules once daily for 2 days followed by 2 capsules once daily for 1 day; 7) patients with body weight of 81-90 kg were given 3 capsules daily for 3 days; and 8) patients with body weight of 91-100 kg were given 4 capsules once daily on the first day followed by 3 capsules once daily for 2 days. Dihydroartemisinin suppositories (Cotecxin) in the study were manufactured by Beijing COTEC New Technology Corporation, China on November 2, 1998. Two doses of mefloquine (Mephaquin, 250 mg/tablet; Mepha, Ltd), 15 mg/kg/dose and 10 mg/kg/dose, were given at 72 hr and 84 hr respectively. The same dose of DHA was re-administered if the suppository came out of the rectum within 1 hr of application. Mefloquine was re-administered if the patient vomited within 1 hr.
Patients were advised to stay in bed for at least 1 hr to ensure that the suppository remained in the rectum. All patients were hospitalized for 28 days to exclude the possibility of reinfection and to assess delayed neuropsychiatric effects. Body temperature, pulse, and respiration rate were evaluated every 4 hr throughout the study. Blood pressure was measured once a day. Signs and symptoms were evaluated every day for the first seven days and weekly thereafter, including a neurologic examination focused on brain stem and cerebellar functions 10 including muscle strength in all limbs, extraocular and facial muscle strength, deep tendon reflexes, and finger-to-nose test. Side effects were defined as signs and symptoms that first occurred or became more severe after treatment started. Cure was defined as the absence of parasite recrudescence during 28 days of follow-up. Pretreatment investigations included complete blood count, electrolytes, total and direct bilirubin, alkaline phosphatase, blood urea nitrogen, creatinine, albumin, globulin, aspartate and alanine aminotransferases, and urine analysis. These tests were repeated daily as necessary for management while the patient was critically ill, and on Day 7, 14, 21, and 28. Thick and thin blood films were prepared and examined for parasites every 6 hr during treatment until negative, then once daily during the 28-day follow-up. Malaria parasite count per microliter was obtained by calculation against the white blood cell count for a thick film. Geometric mean parasite counts were used as a standard method. Blood films were considered negative if no parasites were seen in 200 oil-immersion microscopic fields. Parasite clearance time was defined as the period from the start of treatment until the first negative blood film and negative blood films on 2 more consecutive days. Fever clearance time was taken as the period from the start of treatment until the oral temperature decreased to 37.5ЊC and remained below this temperature for the next 48 hr. Cure rate at Day 28 (cured patients/evaluable patients ϫ 100%) and cure rate at Day 28 for all intent-to-treat (cured patients/enrolled patients ϫ 100%) were determined. In the intent-to-treat analysis, patients who missed their end-of-study visit were considered failures.
RESULTS
One hundred and fifty (150) patients were enrolled. Demographic clinical data and pretreatment laboratory characteristics are shown in Table 1 ; the presence of characteristics of severe and moderately-severe malaria are described in Table 2. Thirty-one patients did not complete the 28-day follow up due to patients' decision (n ϭ 29, all parasitologically negative at the time of withdrawal); deteriorating clinical status (n ϭ 1); and rectal prolapse after DHA suppository insertion (n ϭ 1). Six patients had a late treatment failure (LTF) (RI response). Four of these 6 patients became parasitologically negative and improved clinically on study treatment. Of the remaining two patients, one was discontinued from study medication because of persistent parasitemia after 12 and 18 hr of treatment. Another patient had rectal prolapse. These patients were successfully treated with intravenous artesunate. Patients with late recrudescence were treated with quinine plus tetracycline for seven days. Parasitologic and clinical results are shown in Table 3 . The cure rates at 28 days of follow-up were 95% (113 of 119) for evaluable patients and 75% (113 of 150) on intent to treat basis. One patient with coma and acute renal failure on admission (Glasgow Coma Score ϭ 8) regained consciousness after 6 hr. Two patients with acute renal failure required hemodialysis. Seventy patients had hyperparasitemia with parasite count more than 100,000/L. Forty-three patients had nausea or vomiting that occurred before mefloquine was administered. No deaths occurred. No patients had diarrhea. There were no major adverse drug effects, and no neurologic or neuropsychiatric manifestations during treatment and during the 28-day follow-up period. The results of serial laboratory tests revealed that 103 patients had increased transaminase(s) or total bilirubin levels prior to treatment. These levels returned to normal within 1-2 weeks.
DISCUSSION
Artemisinin derivatives are potent, rapidly acting antimalarials that can reduce parasitemia by more than 90% within 24 hr in uncomplicated malaria cases. However, the rate of recrudescence within 28 days can be reported as high as 10-100% depending upon dosage, duration of treatment, and severity of disease. 3, 4, 6, 11 The more severe the clinical presentation, the higher the recrudescence rate observed. Therefore, these drugs are often combined with mefloquine to shorten treatment course, improve efficacy and compliance, reduce side effects of artemisinin derivatives, and prevent recrudescence. Sequential administration of artesunate followed by mefloquine has been studied in both uncomplicated and severe malaria. [8] [9] [11] [12] [13] [14] [15] To the present, it has remained unclear whether synergy exists between rectal artemisinin derivatives and mefloquine.
In this study, all patients responded satisfactorily to antimalarial treatment. The present study shows a high total cure rate (95%) of DHA suppository in treatment of severe malaria. The cure rate in the present study is similar to our previous report of sequential treatment of severe malaria with artesunate suppository followed by mefloquine. 9 In the previous study, 9 the efficacy of artesunate suppository (200 mg/capsule) given rectally at 0, 4, 8, 12, 24, 36, 48 , and 60 hr (total dose ϭ 1,600 mg or 26-32 mg/kg in 3 days) followed by mefloquine (total dose ϭ 1,250 mg) gave a cure rate, parasite clearance time and fever clearance time of 96%, 47.3 Ϯ 12.4 hr and 71.1 Ϯ 41.2 hr, respectively (comparing with cure rate, parasite clearance time and fever clearance time of 95%, 46.07 Ϯ 15.65 hr and 82.52 Ϯ 59.63 hr respectively in the present study). In both studies there were no fatalities. The dose of DHA suppository in mg/kg in this study is lower than in the artesunate suppository in our previous study 9 ; and DHA can be used once daily for treatment of severe malaria (Li GQ, unpublished data). Therefore, DHA suppositories have the advantage of less frequent administration over artesunate suppositories. Although about half of the patients had parasitemia Ͼ 100,000 L, the mortality in the study was zero-possibly because the patients received early diagnosis and treatment.
The interest in rectal administration in severe malaria is two-fold. First, suppository administration does not require particular skill or sophistication and it can be used as an alternative to parenteral drugs. Second, their availability at the periphery of the health care system to treat patients unable to take oral medication en route to the hospital could prevent progression to severe malaria, thus reducing mortality. Malaria patients who are unable to swallow tablets are at increased risk of dying, 16 which is why malaria patients with severe vomiting were considered as moderately severe malaria.
One problem with suppositories is that the drug may be extruded spontaneously, as occurred after suppository insertion in one study patient who had rectal prolapse. In general, patients who receive suppositories should rest in bed for approximately 1 hr after administration to avoid expulsion. Compared to oral artemisinin, the bioavailability of rectal administration was 30% in uncomplicated malaria, 17 however, there are no published data on the pharmacokinetics of rectal DHA in severe malaria. Therefore, the dose regimen used in this study was based on prior clinical experience (Li GQ, unpublished data).
Artemisinin derivatives have been studied extensively during the past 20 years both in China and elsewhere. 5, 6, 8, [12] [13] [14] [15] It has been estimated that more than one million patients have received at least one of these drugs. 18 Rapid parasite clearance time has been clearly shown with virtually no adverse effects. However, neurotoxicity has been reported in infected animals treated with high doses (5-10 times the doses normally used in humans) of artemether and arteether. 19 In this study, although no adverse neurological effects were observed continued surveillance seems prudent. 18 The results of this study indicate that sequential treatment with DHA suppository followed by mefloquine is effective and well-tolerated. Patients, especially those who are severely ill and have high parasitemia, need to be closely monitored in case they need rescue treatment. However, additional studies (dose ranging, pharmacokinetics, and field trial) are needed in order to get the use of the DHA suppository into general practice.
